Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16913927 | 0.79 | TRPV4 (0.36) | TRPV4ALDH1A1KMT2APIK3CDNPSR1 | |
| SCHEMBL29683113 | 0.79 | TRPV4 (0.36) | TRPV4ALDH1A1KMT2APIK3CDNPSR1 | |
| SCHEMBL22531441 | 0.78 | APLNR (0.38) | APLNRTRPV4ALDH1A1KMT2A | |
| SCHEMBL21713598 | 0.76 | ALDH1A1 (0.38) | APLNRTRPV4ALDH1A1KMT2APIK3CD | |
| SCHEMBL789628 | 0.76 | ALPL (0.47) | ALDH1A1KMT2ANPSR1 | |
| SCHEMBL21713760 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KMT2A | |
| SCHEMBL31306047 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KMT2A | |
| SCHEMBL22532346 | 0.74 | TRPV4 (0.38) | APLNRTRPV4PIK3CA | |
| SCHEMBL30989845 | 0.72 | TRPV4 (0.56) | APLNRTRPV4PIK3CA | |
| SCHEMBL20304553 | 0.72 | ALPL (0.41) | APLNRTRPV4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| US-20220315604-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| US-11427601-B1 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-30 | — | — | US | disclosed |
| EP-3833662-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica N.V. (BE) | 2021-06-16 | — | — | EP | disclosed |
| CN-112930347-A | Inhibitors of KEAP1-Nrf2 protein-protein interactions | 詹森药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-16 | — | — | US | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315604-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | APLNR 4278/4885TRPV4 4403/4885ALDH1A1 1271/4885 |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | APLNR 4278/4885TRPV4 4403/4885ALDH1A1 1271/4885 |
| US-11427601-B1 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | APLNR 4278/4885TRPV4 4403/4885ALDH1A1 1271/4885 |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | APLNR 4278/4885TRPV4 4403/4885ALDH1A1 1271/4885 |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | APLNR 4278/4885TRPV4 4403/4885ALDH1A1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.